Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DISCO: 64Cu-SARTATE PET in GEP-NETs
NCT04438304Phase 2Completed
- Sponsor
- Clarity Pharmaceuticals
- Start
- Mar 2021
- Primary completion
- Nov 2024
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 2, open-label trial of Cu-64 sartate in neuroendocrine tumors (NETs), sponsored by Clarity Pharmaceuticals. Primary endpoints: Comparison of diagnostic performance of 64Cu-SARTATE to that of 68Ga-DOTATATE on a per-lesion basis for discordant findings at 4 hours and Proportion of concordance between 4-hour 64Cu-SARTATE to that of 68Ga-DOTATATE. Started Mar 2021; status: completed.
02
Drugs
Cu-64 sartate
03
Conditions
neuroendocrine tumors (NETs)
Beyond the preview
Go deeper on NCT04438304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04438304.